Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy

David Bomze, Luciano Mutti, Adam Goldman, Gal Markel, Tomer Meirson

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Access to Document

@article{7c84e926afc64defba3fae697ef203cb,

title = "Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy",

author = "David Bomze and Luciano Mutti and Adam Goldman and Gal Markel and Tomer Meirson",

year = "2022",

month = jun,

doi = "10.1016/s1470-2045(22)00258-3",

language = "אנגלית",

volume = "23",

pages = "e245",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd.",

number = "6",

}

TY - JOUR

T1 - Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy

AU - Bomze, David

AU - Mutti, Luciano

AU - Goldman, Adam

AU - Markel, Gal

AU - Meirson, Tomer

PY - 2022/6

Y1 - 2022/6

UR - https://www.scopus.com/pages/publications/85130891253

U2 - 10.1016/s1470-2045(22)00258-3

DO - 10.1016/s1470-2045(22)00258-3

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 35654062

AN - SCOPUS:85130891253

SN - 1470-2045

VL - 23

SP - e245

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 6

ER -